This study is looking at a new medicine called ziltivekimab for people with heart failure and inflammation. Heart failure is when the heart doesn't pump blood as well as it should. Inflammation is when the body's tissues become swollen and painful. Participants will be chosen randomly to receive either ziltivekimab or a placebo. A placebo looks like the medicine but doesn't have any active ingredients. The study lasts about 1 year and 4 months, during which participants will be monitored to see how well the medicine works compared to the placebo.
- Study Length: Up to 1 year and 4 months
- Randomized Treatment: Participants will receive either ziltivekimab or placebo
- Eligibility: Specific health conditions related to heart failure and inflammation are required
Before deciding to participate, consider the study length, the randomized treatment process, and the specific health criteria needed to join. This medicine is experimental and not yet approved by doctors anywhere. Participation could help researchers understand if ziltivekimab is a useful treatment for heart failure with inflammation.